Last reviewed · How we verify
Eicosapentaenoic acid gastro-resistant capsules
Eicosapentaenoic acid gastro-resistant capsules is a Omega-3 fatty acid Small molecule drug developed by S.L.A. Pharma AG. It is currently in Phase 3 development for Hypertriglyceridemia (elevated triglycerides), Cardiovascular risk reduction in patients with elevated triglycerides. Also known as: Alfa.
Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways in cardiovascular disease.
Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways in cardiovascular disease. Used for Hypertriglyceridemia (elevated triglycerides), Cardiovascular risk reduction in patients with elevated triglycerides.
At a glance
| Generic name | Eicosapentaenoic acid gastro-resistant capsules |
|---|---|
| Also known as | Alfa |
| Sponsor | S.L.A. Pharma AG |
| Drug class | Omega-3 fatty acid |
| Target | Multiple targets including triglyceride metabolism and inflammatory pathways |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
EPA is incorporated into cell membranes and acts as a substrate for the production of anti-inflammatory eicosanoids, reducing triglyceride synthesis in the liver and decreasing circulating triglyceride levels. The gastro-resistant formulation protects the active ingredient from degradation in the stomach, allowing targeted delivery to the small intestine for optimal absorption. This mechanism helps reduce cardiovascular risk in patients with elevated triglycerides.
Approved indications
- Hypertriglyceridemia (elevated triglycerides)
- Cardiovascular risk reduction in patients with elevated triglycerides
Common side effects
- Gastrointestinal upset
- Fishy aftertaste
- Bleeding risk (at high doses)
Key clinical trials
- Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis (PHASE3)
- EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eicosapentaenoic acid gastro-resistant capsules CI brief — competitive landscape report
- Eicosapentaenoic acid gastro-resistant capsules updates RSS · CI watch RSS
- S.L.A. Pharma AG portfolio CI
Frequently asked questions about Eicosapentaenoic acid gastro-resistant capsules
What is Eicosapentaenoic acid gastro-resistant capsules?
How does Eicosapentaenoic acid gastro-resistant capsules work?
What is Eicosapentaenoic acid gastro-resistant capsules used for?
Who makes Eicosapentaenoic acid gastro-resistant capsules?
Is Eicosapentaenoic acid gastro-resistant capsules also known as anything else?
What drug class is Eicosapentaenoic acid gastro-resistant capsules in?
What development phase is Eicosapentaenoic acid gastro-resistant capsules in?
What are the side effects of Eicosapentaenoic acid gastro-resistant capsules?
What does Eicosapentaenoic acid gastro-resistant capsules target?
Related
- Drug class: All Omega-3 fatty acid drugs
- Target: All drugs targeting Multiple targets including triglyceride metabolism and inflammatory pathways
- Manufacturer: S.L.A. Pharma AG — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertriglyceridemia (elevated triglycerides)
- Indication: Drugs for Cardiovascular risk reduction in patients with elevated triglycerides
- Also known as: Alfa
- Compare: Eicosapentaenoic acid gastro-resistant capsules vs similar drugs
- Pricing: Eicosapentaenoic acid gastro-resistant capsules cost, discount & access